A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Colorectal cancer (CRC) is a significant global health challenge.
• Carcinoembryonic antigen (CEA) is overexpressed in many CRC tumors.
• Developing effective immunotherapies for CEA-positive tumors remains a critical need.

Purpose of the Study:

• To evaluate a novel genetic vaccine platform combining DNA electroporation (DNA-EP) and adenovirus (Ad) for cancer immunotherapy.
• To assess the efficacy of targeting CEA in preclinical models of spontaneous colorectal cancer.
• To investigate the potential of breaking immune tolerance against tumor-associated antigens.

Main Methods:

• Utilized two distinct murine models: 1,2-dimethylhydrazine-induced CEA-overexpressing tumors and APC1638N/CEA hybrid mice representing familial polyposis.
• Administered a combined DNA-EP/Ad genetic vaccine targeting human CEA.
• Assessed immune response and antitumor effects in therapeutic settings.

Main Results:

• The DNA-EP/Ad vaccine successfully elicited an immune response against CEA in both tumor models.
• Significant therapeutic antitumor effects were observed, demonstrating the vaccine's efficacy.
• Immune tolerance against CEA was effectively overcome by the vaccination strategy.

Conclusions:

• Genetic vaccines targeting CEA, delivered via DNA-EP/Ad platform, demonstrate feasibility and efficacy against relevant colorectal cancer models.
• These findings support the potential of CEA-targeted genetic vaccines as a therapeutic strategy for CEA-overexpressing gut tumors.
• The established murine models serve as valuable tools for further research in antigen-specific tumor immunity and therapeutic vaccine development for CRC.